To date, a phase I/IIa clinical trial (NCT02452424) has evaluated the efficacy of this combination therapy—CSF1R and the immunotherapeutic agent pembrolizumab—in patients with solid tumors, including melanoma. Here, CSF1R is linked to melanoma.